Table 5 |
|||||||
Efficacy of atypical antipsychotics in elderly patients with dementia: Number needed to treat | |||||||
Study | Study Design | Follow-up | Risperidone n/N (%) | Placebo n/N (%) | RD | NNT | |
Clinical End Point | |||||||
>50% Improvement in Behave-AD^{1}total score | |||||||
Katz [62] | Double-blind placebo controlled RCT (n=625) | 12 weeks | (45%) | (33%) | 12% | 8 | |
Schneider [6] | Meta Analysis of 3 studies (n=1001) | 12 weeks | 266/574 (46%) | 139/427 (33%) | 14% | 7.4 | |
>30% Improvement in Behave-AD^{1}total score | |||||||
DeDeyn [8] | Double-blind placebo controlled RCT (n=344) | 12 weeks | (72%) | (61%) | 11% | 9 | |
CGI-C^{2} (much/very much improved) | |||||||
Brodaty [61] | Double-blind placebo controlled RCT (n=93) | 12 weeks | 27/46 (59%) | 12/47 (26%) | 33% | 3.3 | |
Schneider [6] | Meta Analysis of 2 studies (n=717) | 8-12 weeks | 227/351 (65%) | 175/366 (48%) | 17% | 6 | |
Katz [5] | Meta Analysis of 4 studies (n=889) | End point | (28%) | (17%) | 11% | 9 | |
Sultzer [63] | Double-blind placebo controlled RCT (n=421) | 12 weeks | (61%) | (40%) | 21% | 5 |
^{1} BEHAVE-AD: Behaviour Pathology in Alzheimerâ€™s Disease Rating Scale.
^{2} CGI-C: Clinical Global Impression of Change.
Pratt et al.
Pratt et al. BMC Medical Research Methodology 2012 12:72 doi:10.1186/1471-2288-12-72